MetaVia reports 1.47 mg/dL placebo‑adjusted uric acid reduction in Phase 1 trial of DA‑1726
+1 new source since this summary was written
MetaVia Inc. announced that its dual GLP‑1/glucagon agonist DA‑1726 lowered serum uric acid by 1.47 mg/dL versus placebo after 16 weeks in a Phase 1 Part 3B study of obese adults. The trial also confirmed earlier findings of a 68.1% placebo‑adjusted liver‑fat reduction and a 13.5% weight loss. The company plans to begin a 48‑week, non‑biopsy Phase 2 study in up to 150 MetALD and ALD patients in the second half of 2027 and will release full Phase 1 data in the first quarter of 2027.
Why it matters
MetaVia says the uric‑acid result strengthens the metabolic profile of DA‑1726 and supports its advancement into Phase 2 (the company’s filing states the Phase 2 start is targeted for H2 2027). Full Phase 1 data are expected in Q1 2027, which could influence investor sentiment and valuation.
Key facts
- 1DA‑1726 produced a placebo‑adjusted reduction in serum uric acid of 1.47 mg/dL after 16 weeks (p<0.001). prnewswire.com
- 2Mean uric acid fell by 1.02 mg/dL from a baseline of 5.89 mg/dL in the DA‑1726 group, while the placebo group rose 0.45 mg/dL from a baseline of 4.80 mg/dL. sec.gov
- 3The analysis included 15 participants receiving DA‑1726 and four receiving placebo. prnewswire.com
- 4Previously reported interim results showed a 68.1% placebo‑adjusted reduction in liver fat (p<0.001). prnewswire.com
- 5The same interim data showed a 13.5% placebo‑adjusted weight loss (p<0.001). sec.gov
- 6MetaVia plans a 48‑week, non‑biopsy Phase 2 study in up to 150 MetALD and ALD subjects, targeted to begin in the second half of 2027. sec.gov
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.